$787 Million is the total value of BVF INC/IL's 37 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 44.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Buy | ARRAY BIOPHARMA INC | $78,751,000 | +55.3% | 6,402,525 | +5.7% | 10.01% | +27.1% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $70,182,000 | -13.0% | 1,007,354 | -36.7% | 8.92% | -28.8% |
| CCXI | Sell | CHEMOCENTRYX INC | $56,299,000 | -27.1% | 7,587,416 | -8.0% | 7.16% | -40.3% |
| ANAB | Sell | ANAPTYSBIO INC | $48,201,000 | +21.4% | 1,379,134 | -16.9% | 6.13% | -0.6% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $46,246,000 | +78.5% | 3,135,289 | +68.8% | 5.88% | +46.1% |
| GLYC | Buy | GLYCOMIMETICS INC | $45,186,000 | +36.3% | 3,229,856 | +8.7% | 5.74% | +11.6% |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $44,471,000 | – | 2,820,000 | +100.0% | 5.65% | – |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $40,535,000 | +29.0% | 2,230,898 | +10.1% | 5.15% | +5.6% |
| XOMA | XOMA CORP DEL | $29,530,000 | +181.1% | 1,502,800 | 0.0% | 3.75% | +130.2% | |
| BLRX | Buy | BIOLINERX LTDsponsored adr | $29,115,000 | +95.7% | 25,995,575 | +48.5% | 3.70% | +60.2% |
| CTIC | CTI BIOPHARMA CORP | $27,422,000 | -3.6% | 8,596,357 | 0.0% | 3.49% | -21.1% | |
| LOXO | Sell | LOXO ONCOLOGY INC | $21,960,000 | -40.9% | 238,386 | -48.6% | 2.79% | -51.6% |
| KURA | New | KURA ONCOLOGY INC | $20,240,000 | – | 1,353,846 | +100.0% | 2.57% | – |
| OMED | New | ONCOMED PHARMACEUTICALS INC | $19,889,000 | – | 4,400,289 | +100.0% | 2.53% | – |
| ZEAL | New | ZEALAND PHARMA A Ssponsored adr | $19,200,000 | – | 1,000,000 | +100.0% | 2.44% | – |
| CYTK | Sell | CYTOKINETICS INC | $17,995,000 | -25.3% | 1,241,021 | -37.6% | 2.29% | -38.9% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $17,203,000 | -2.6% | 2,986,562 | -14.5% | 2.19% | -20.3% |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $16,187,000 | +400.8% | 12,949,229 | +294.9% | 2.06% | +310.0% |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $14,991,000 | – | 950,000 | +100.0% | 1.90% | – |
| TOCA | Sell | TOCAGEN INC | $13,245,000 | -13.9% | 1,063,028 | -16.9% | 1.68% | -29.5% |
| CASC | CASCADIAN THERAPEUTICS INC | $12,815,000 | +10.1% | 3,133,224 | 0.0% | 1.63% | -9.9% | |
| SBPH | Buy | SPRING BK PHARMACEUTICALS INC | $10,991,000 | +31.9% | 652,676 | +6.1% | 1.40% | +8.0% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $10,587,000 | -4.5% | 3,588,830 | +2.0% | 1.35% | -21.8% |
| INFI | INFINITY PHARMACEUTICALS INC | $10,462,000 | -15.3% | 7,866,108 | 0.0% | 1.33% | -30.7% | |
| GTXI | GTX INC DEL | $9,111,000 | +55.4% | 1,108,433 | 0.0% | 1.16% | +27.1% | |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $8,571,000 | -69.6% | 1,455,117 | +4.8% | 1.09% | -75.1% |
| ARQL | ARQULE INC | $8,214,000 | -10.5% | 7,400,128 | 0.0% | 1.04% | -26.7% | |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $7,839,000 | – | 675,759 | +100.0% | 1.00% | – |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $7,323,000 | +120.7% | 459,396 | +67.5% | 0.93% | +80.8% |
| MTEM | New | MOLECULAR TEMPLATES INC | $5,047,000 | – | 724,132 | +100.0% | 0.64% | – |
| New | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $4,769,000 | – | 10,000,000 | +100.0% | 0.61% | – | |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $3,964,000 | -17.1% | 2,043,196 | +15.4% | 0.50% | -32.1% |
| CFRX | New | CONTRAFECT CORP | $3,885,000 | – | 3,500,000 | +100.0% | 0.49% | – |
| ADRO | Sell | ADURO BIOTECH INC | $1,968,000 | -42.5% | 184,764 | -38.4% | 0.25% | -52.9% |
| OREXQ | OREXIGEN THERAPEUTICS INC | $1,558,000 | -26.9% | 734,976 | 0.0% | 0.20% | -40.2% | |
| ANTH | ANTHERA PHARMACEUTICALS INC | $1,449,000 | -11.2% | 1,006,507 | 0.0% | 0.18% | -27.3% | |
| PTIE | PAIN THERAPEUTICS INC | $1,325,000 | -1.2% | 325,508 | 0.0% | 0.17% | -19.2% | |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -391,386 | -100.0% | -0.20% | – |
| Exit | OREXIGEN THERAPEUTICS INCnote 2.750% | $0 | – | -10,000,000 | -100.0% | -0.78% | – | |
| NVLS | Exit | NIVALIS THERAPEUTICS INC | $0 | – | -2,644,806 | -100.0% | -0.99% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -700,000 | -100.0% | -1.12% | – |
| OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -4,400,289 | -100.0% | -2.28% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -3,490,077 | -100.0% | -2.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.